ZNTL$4.64
$4.749
Chart
Performance
Key Stats
AI ZNTL Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
HoldZentalis Pharmaceuticals is in a critical clinical stage with ongoing trials for its lead candidate. While its thematic relevance in cancer therapy is strong, current financial performance and valuation metrics suggest a 'Hold' rating. Investors should monitor clinical trial progress and regulatory approvals closely.
Thematic
Zentalis Pharmaceuticals is positioned within the high-growth and critically important biopharmaceutical sector, specifically focusing on oncology. Its lead candidate targets significant unmet needs in cancer treatment.
Fundamental
Zentalis Pharmaceuticals is a clinical-stage company with no current revenue, leading to significant net losses and negative EPS. Its balance sheet shows substantial assets, but cash burn is a concern. The lack of profitability makes traditional valuation metrics like P/E ratios not applicable.
Technical
The stock exhibits mixed technical signals. While some shorter-term moving averages suggest bullish momentum, longer-term trends and oscillators are more neutral to slightly bearish, indicating potential price volatility and a need for careful entry points.
| Factor | Score |
|---|---|
| Oncology Drug Development | 85 |
| Targeted Therapy Innovation | 80 |
| Partnerships and Collaborations | 70 |
| Biotech Market Trends | 70 |
| Regulatory Landscape | 70 |
| Factor | Score |
|---|---|
| Valuation | 40 |
| Profitability | 10 |
| Growth | 20 |
| Balance Sheet Health | 70 |
| Cash Flow | 30 |
| Factor | Score |
|---|---|
| Trend Analysis | 40 |
| Momentum | 60 |
| Volume Confirmation | 50 |
| Support & Resistance | 70 |
| Short-term Signals | 75 |
AI Investing Checklist
Powered by LiveAIBullish Points (7)
Recent Positive Momentum
The stock has shown a 24.58% increase in the last month, indicating strong recent performance.
Focus on Cancer Therapeutics
Zentalis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for cancer, a significant and growing area in healthcare.
Bearish Points (8)
Consistent Net Losses
Zentalis Pharmaceuticals has consistently reported net losses, with a significant net loss of -$165.84 million in Q4 2024, and negative EPS (EPS TTMTM: -3.14), indicating ongoing unprofitability.
Negative P/E Ratio
The Price-to-Earnings (P/E) ratio is negative (TTM: -0.8, 2024: -1.3, 2023: -0.4), which is typical for unprofitable companies and makes traditional P/E valuation analysis difficult.
Calendar
August 2025
7
Next Earnings Date
H: $-0.43
A: $-0.52
L: $-0.81
Profile
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. The company develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types. It also develops ZN-c3-001, a phase 1 study that evaluated azenosertib monotherapy in solid tumors; and MAMMOTH (ZN-c3-006) is a Phase 1/2 clinical trial of azenosertib in patients with PARP-inhibitor resistant ovarian cancer. It has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC. Zentalis Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
Seasonals
Price Target
6.31 USD
The 39 analysts offering 1 year price forecasts for ZNTL have a max estimate of 10.00 and a min estimate of 2.50.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Cash Flow
Related Companies
Powered by LiveAIWeight: 95
Clinical-stage biotechnology company focused on synthetic lethality, including DNA Damage Response (DDR) pathways, directly overlapping with ZNTL's strategic focus on WEE1 and other DDR targets.
Weight: 93
Clinical-stage biotechnology company focused on synthetic lethality and targeted oncology, particularly in DDR and precision oncology, making it a close peer to ZNTL.
Weight: 90
Clinical-stage precision oncology company utilizing a novel drug discovery platform for small molecule therapeutics, addressing similar target discovery challenges as ZNTL.
Weight: 88
Clinical-stage precision oncology company developing small molecule inhibitors for the RAS pathway, a key area of targeted oncology similar to ZNTL's approach.